I think if we want to build something that actually responds to all Canadians' needs and make sure they have access to innovative medicines in a national program, we definitely have to move it through without the common drug review.
As Mr. Brenders talked about, it's a different philosophy, and I think what we have to do is sit down and build together with each of the provinces the method that responds to those priorities.